Crispr Therapeutics AG vs WD 40 Company — how do they compare? Crispr Therapeutics AG trades at $54.22 (market cap $5.23B), while WD 40 Company trades at $233.59 (market cap $3.13B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and WD 40 Company pays a 1.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WDFC | |
|---|---|---|
Market Cap | $5.23B | $3.13B |
Sector | Health | Technology |
52-Week High | $76.78 | $264.91 |
52-Week Low | $44.34 | $187.52 |
Enterprise Value | $3.65B | $3.18B |
Dividend Yield | — | 1.75% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →